CryoPort Names Life Sciences/Clean Tech Veteran Larry Stambaugh as Chairman of the Board

Mr. Stambaugh Is a Recognized Leader in Corporate Governance

LAKE FOREST, CA -- (MARKET WIRE) -- 12/09/08 -- CryoPort, Inc. (OTCBB: CYRX) today announced it has named Larry Stambaugh to the Board of Directors. Mr. Stambaugh has also been elected to the position of Chairman of the Board.

Mr. Stambaugh is currently a Principal of Apercu Consulting and sits on the boards of several companies. At Apercu, Mr. Stambaugh serves as an advisor to several private and public boards and CEOs, concentrating on strategic business direction, turnarounds and board governance. Mr. Stambaugh brings to CryoPort more than 30 years of successful experience building global businesses and setting strategies. He also brings an extensive background in life sciences and clean tech including relationships with and knowledge of Contract Research Organizations, and biotech and pharmaceutical companies.

Peter Berry, CEO of CryoPort, stated, "Recruiting a successful and experienced biotech/clean tech executive like Larry Stambaugh to join our Board of Directors at this time will enhance CryoPort's ability to move from an early revenue stage company to full global commercialization. We are extremely pleased to announce that Mr. Stambaugh has agreed to join the Board of Directors."

"I believe that CryoPort has an exciting opportunity to launch a game changing and environmentally friendly product in the global frozen shipment business," stated Mr. Stambaugh. "I look forward to working with the board and management on the challenges of growing the company and creating shareholder value."

To be added to the CryoPort Investor email list, please email

About CryoPort, Inc.

CryoPort ( is commercializing proprietary, technology-driven frozen shipping and storage products for use in the rapidly growing global biotechnology and biopharmaceutical cold chain. The products developed by CryoPort are essential components of the infrastructure required for the testing, research and end user delivery of temperature-sensitive medicines and biomaterials in an increasingly complex logistical environment.


This press release contains forward-looking statements. The words "estimate," "possible" and "seeking" and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Stuart Fine
Carpe DM, Inc.